Fundz

LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer

PRIVATEApr 07, 2025

Position

Chief Scientific Officer

Company

LIfT BioSciences

Mark A. Exley
mexley@liftbiosciences.com
LondonBiotechnologyHealth CareTherapeutics

Description

LIfT BioSciences has announced the appointment of Mark A. Exley as Chief Scientific Officer, effective 7 April 2025. His extensive clinical expertise comes at a crucial time as the company advances its clinical trials.

Quick answer

LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer (April 7, 2025). LIfT BioSciences is based in London, England, United Kingdom.

Who is the new Chief Scientific Officer at LIfT BioSciences?
LIfT BioSciences named Mark A. Exley Chief Scientific Officer, announced April 7, 2025.
What did LIfT BioSciences announce on April 7, 2025?
LIfT BioSciences has announced the appointment of Mark A. Exley as Chief Scientific Officer, effective 7 April 2025. His extensive clinical expertise comes at a crucial time as the company advances its clinical trials.
What does LIfT BioSciences do?
LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly.
Where is LIfT BioSciences based?
LIfT BioSciences is based in London, England, United Kingdom.
Which similar companies made leadership changes around the same time?
TuHURA Biosciences (April 7, 2025), Artiva Biotherapeutics (April 8, 2025), Merakris Therapeutics (April 10, 2025) and Rocket Pharmaceuticals (April 10, 2025) also announced leadership changes within 45 days of LIfT BioSciences.

Source: Fundz verified event record.

Other recent leadership changes in Therapeutics and Biotechnology

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at LIfT BioSciences, and when

A new leader at LIfT BioSciences brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day LIfT BioSciences raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at LIfT BioSciences, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at LIfT BioSciences. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

LIfT BioSciences

Location

London, England, United Kingdom

About

LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering (e.g. CARs). The resulting CAR-IMAN cells give cancer patients potentially hundreds of times the cancer killing ability they naturally possess.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment LIfT BioSciences changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Mark
Likely contact at this company
••••••••@••••••••

See Mark's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for LIfT BioSciences's next move

Learn about Strategic plan

LIfT BioSciences changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.